{"title":"既定的他汀类药物使用降低社区获得性肺炎的死亡率:一项系统回顾和荟萃分析","authors":"E. Fitzgerald, L. Duquette, Matthew Williams","doi":"10.33590/emjrespir/10311855","DOIUrl":null,"url":null,"abstract":"Background: Statin therapy (ST) has been associated with improved outcomes from sepsis. Our objective was to systematically review the association between established ST and outcomes of patients with community-acquired pneumonia (CAP) that is severe enough to require hospitalisation.\nMethods: Two meta-analyses were conducted following a search of articles published before 31st January 2013. After exclusions, seven studies were included to assess the effects of statins on 30-day mortality from CAP, and eight studies were included to assess the effects of statins on the development of CAP. Endpoints were a reduction in the risk of 30-day mortality or risk of developing CAP.\nResults: A reduction in the risk of 30-day mortality from CAP was identified in patients established on ST (pooled odds ratio [OR]: 0.70, 95% confidence interval [CI]: 0.65-0.76; adjusted OR: 0.58, 95% CI: 0.47-0.69). The pooled OR for risk of developing CAP in patients with and without established ST was 1.01 (95% CI: 0.98-1.04).\nConclusion: There appears to be weak evidence to suggest a potential benefit of established ST. It is associated with a reduced risk of 30-day mortality in patients subsequently hospitalised with CAP. Further evidence is required, but ST could be considered as a means of reducing the risk of mortality from pneumonia.","PeriodicalId":300382,"journal":{"name":"EMJ Respiratory","volume":"409 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2015-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Established Statin Use Reduces Mortality From Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis\",\"authors\":\"E. Fitzgerald, L. Duquette, Matthew Williams\",\"doi\":\"10.33590/emjrespir/10311855\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Statin therapy (ST) has been associated with improved outcomes from sepsis. Our objective was to systematically review the association between established ST and outcomes of patients with community-acquired pneumonia (CAP) that is severe enough to require hospitalisation.\\nMethods: Two meta-analyses were conducted following a search of articles published before 31st January 2013. After exclusions, seven studies were included to assess the effects of statins on 30-day mortality from CAP, and eight studies were included to assess the effects of statins on the development of CAP. Endpoints were a reduction in the risk of 30-day mortality or risk of developing CAP.\\nResults: A reduction in the risk of 30-day mortality from CAP was identified in patients established on ST (pooled odds ratio [OR]: 0.70, 95% confidence interval [CI]: 0.65-0.76; adjusted OR: 0.58, 95% CI: 0.47-0.69). The pooled OR for risk of developing CAP in patients with and without established ST was 1.01 (95% CI: 0.98-1.04).\\nConclusion: There appears to be weak evidence to suggest a potential benefit of established ST. It is associated with a reduced risk of 30-day mortality in patients subsequently hospitalised with CAP. Further evidence is required, but ST could be considered as a means of reducing the risk of mortality from pneumonia.\",\"PeriodicalId\":300382,\"journal\":{\"name\":\"EMJ Respiratory\",\"volume\":\"409 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-05-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMJ Respiratory\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33590/emjrespir/10311855\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Respiratory","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjrespir/10311855","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Established Statin Use Reduces Mortality From Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis
Background: Statin therapy (ST) has been associated with improved outcomes from sepsis. Our objective was to systematically review the association between established ST and outcomes of patients with community-acquired pneumonia (CAP) that is severe enough to require hospitalisation.
Methods: Two meta-analyses were conducted following a search of articles published before 31st January 2013. After exclusions, seven studies were included to assess the effects of statins on 30-day mortality from CAP, and eight studies were included to assess the effects of statins on the development of CAP. Endpoints were a reduction in the risk of 30-day mortality or risk of developing CAP.
Results: A reduction in the risk of 30-day mortality from CAP was identified in patients established on ST (pooled odds ratio [OR]: 0.70, 95% confidence interval [CI]: 0.65-0.76; adjusted OR: 0.58, 95% CI: 0.47-0.69). The pooled OR for risk of developing CAP in patients with and without established ST was 1.01 (95% CI: 0.98-1.04).
Conclusion: There appears to be weak evidence to suggest a potential benefit of established ST. It is associated with a reduced risk of 30-day mortality in patients subsequently hospitalised with CAP. Further evidence is required, but ST could be considered as a means of reducing the risk of mortality from pneumonia.